Cascadian Therapeutics strengthens management team
Ms. Greer will be a member of the Company's executive committee. Ms. Greer, a veteran biopharmaceutical executive, joins Cascadian Therapeutics with over 20 years of experience driving communications strategies and initiatives.
She has played an active role in several successful financing rounds and helped launch multiple drugs in the U.S. and Europe.
Ms. Greer was most recently Senior Vice President of Corporate Communications and Investor Relations at CTI BioPharma Corp., where she led the company's corporate, investor and product communications.
She also served in similar functions at Allos Therapeutics, Inc. (acquired by Spectrum Pharmaceuticals); WCG, a global communications agency; Dendreon Corporation and Heska Corporation.
Dr. Chamberlain was most recently Professor of Neurology and Neurological Surgery at the University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance in Seattle, Washington.
Dr. Chamberlain has developed many of the methods used today in evaluating and managing neoplastic meningitis.
He has focused increasingly on clinical trials for primary brain tumors, hoping to achieve new and better therapies. He has published his work in more than 350 scientific papers in peer-reviewed publications.
Dr. Chamberlain received his medical degree in from Columbia University, College of Physicians and Surgeons in New York.